Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (Articolo in rivista)

Type

• Prodotto della ricerca (Classe)
• Articolo in rivista (Classe)

Label

• Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (Articolo in rivista) (literal)

Anno

• 2002-01-01T00:00:00+01:00 (literal)

Alternative label

• Basolo F. 1, Giannini R. 1, Monaco C. 5, Melillo R.M. 5, Carlomagno F. 5, Pancrazi M. 1, Salvatore G. 5, Chiappetta G. 4, Pacini F. 2, Elisei R. 2, Miccoli P. 3, Pinchera A. 2, Fusco A. 5, Santoro M. 5 (2002)
  Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma.
  
  (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

• Basolo F. 1, Giannini R. 1, Monaco C. 5, Melillo R.M. 5, Carlomagno F. 5, Pancrazi M. 1, Salvatore G. 5, Chiappetta G. 4, Pacini F. 2, Elisei R. 2, Miccoli P. 3, Pinchera A. 2, Fusco A. 5, Santoro M. 5 (literal)

Pagina inizio

• 247 (literal)

Pagina fine

• 254 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#altreInformazioni

• Impact Factor = 7,103; Interdisciplinarietà del prodotto: The Authors belong to different scientific areas, sectors and Istitutions. (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

• 160 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#descrizioneSinteticaDelProdotto

• The tall-cell variant (TCV) of papillary thyroid carcinoma (PTC), characterized by tall cells bearing an oxyphilic cytoplasm, is more clinically aggressive than conventional PTC. RET tyrosine kinase rearrangements, which represent the most frequent genetic alteration in PTC, lead to the recombination of RET with heterologous genes to generate chimeric RET/PTC oncogenes. RET/PTC1 and RET/PTC3 are the most prevalent variants. We have found RET rearrangements in 35.8% of TCV (14 of 39 cases). Whereas the prevalences of RET/PTC1 and RET/PTC3 were almost equal in classic and follicular PTC, all of the TCV-positive cases expressed the RET/PTC3 rearrangement. These findings prompted us to compare RET/PTC3 and RET/PTC1 in an in vitro thyroid model system. We have expressed the two oncogenes in PC Cl 3 rat thyroid epithelial cells and found that RET/PTC3 is endowed with a strikingly more potent mitogenic effect than RET/PTC1. Mechanistically, this difference correlated with an increased signaling activity of RET/PTC3. In conclusion, we postulate that the correlation between the RET/PTC rearrangement type and the aggressiveness of human PTC is related to the efficiency with which the oncogene subtype delivers mitogenic signals to thyroid cells. (literal)

Note

• ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

• 1 Dipartimento di Oncologia, Università degli Studi di Pisa; 2 Istituto di Endocrinologia,Università degli Studi di Pisa; 3 Dipartimento di Chirurgia, Università degli Studi di Pisa; 4 INT di Napoli, Fondazione Senatore Pascale, Naples; 5 Centro di Endocrinologia ed Oncologia Sperimentale del CNR c/o Dipartimento di Biologia e Patologia Cellulare e Molecolare, Università degli Studi di Napoli \"Federico II\", Italy (literal)

Titolo

• Potent mitogenicity of the RET/PTC3 oncogene correlates with its prevalence in tall-cell variant of papillary thyroid carcinoma. (literal)

Abstract

• The tall-cell variant (TCV) of papillary thyroid carcinoma (PTC), characterized by tall cells bearing an oxyphilic cytoplasm, is more clinically aggressive than conventional PTC. RET tyrosine kinase rearrangements, which represent the most frequent genetic alteration in PTC, lead to the recombination of RET with heterologous genes to generate chimeric RET/PTC oncogenes. RET/PTC1 and RET/PTC3 are the most prevalent variants. We have found RET rearrangements in 35.8% of TCV (14 of 39 cases). Whereas the prevalences of RET/PTC1 and RET/PTC3 were almost equal in classic and follicular PTC, all of the TCV-positive cases expressed the RET/PTC3 rearrangement. These findings prompted us to compare RET/PTC3 and RET/PTC1 in an in vitro thyroid model system. We have expressed the two oncogenes in PC Cl 3 rat thyroid epithelial cells and found that RET/PTC3 is endowed with a strikingly more potent mitogenic effect than RET/PTC1. Mechanistically, this difference correlated with an increased signaling activity of RET/PTC3. In conclusion, we postulate that the correlation between the RET/PTC rearrangement type and the aggressiveness of human PTC is related to the efficiency with which the oncogene subtype delivers mitogenic signals to thyroid cells. (literal)

Prodotto di

• Istituto per l'endocrinologia e l'oncologia \"Gaetano Salvatore\" (IEOS) (Istituto)

Autore CNR

• FRANCESCA CARLOMAGNO (Persona)
• ROSA MARINA MELILLO (Persona)
• GIULIANA SALVATORE (Unità di personale interno)
• MASSIMO SANTORO (Unità di personale interno)

Incoming links:

Autore CNR di

• ROSA MARINA MELILLO (Persona)
• GIULIANA SALVATORE (Unità di personale interno)
• FRANCESCA CARLOMAGNO (Persona)
• MASSIMO SANTORO (Unità di personale interno)

Prodotto

• Istituto per l'endocrinologia e l'oncologia \"Gaetano Salvatore\" (IEOS) (Istituto)